04 | MD Anderson Cancer Center Skip to Content
Top

BY MD Anderson staff

A number of MD Anderson physicians and scientists chaired or co-chaired sessions and presented research, ranging from racial disparities in the quality of life of minority colorectal cancer patients to a potential druggable target for prostate cancer, at the American Association of Cancer Research Annual Meeting earlier this month in Washington, D.C.

In addition, Gordon Mills, M.D., Ph.D., chair of Systems Biology, was elected...

combination immunotherapy for kidney cancer

BY Clayton Boldt, Ph.D.

This year, for the first time in Texas, lawmakers have proposed legislation that would raise the state’s minimum legal age to buy tobacco...

BY MD Anderson Staff

A type of functional brain training known as neurofeedback shows promise in reducing symptoms of chemotherapy-induced nerve damage, or neuropathy...

BY Leslie Loddeke

Stories of immunotherapy’s success against metastatic melanoma in patients such as former President Jimmy Carter are well publicized, but the treatment doesn’t work for everyone.

In fact, checkpoint blockade drugs such as pembrolizumab and nivolumab, which inhibit protein molecules on T cells that keep the immune system from attacking tumors, only work for about one-third of patients.

Why do some tumors respond...

immunotherapy melanoma

BY Ron Gilmore

The biopharmaceutical drug blinatumomab is more effective for the treatment of relapsed or treatment-resistant acute lymphoblastic leukemia...

BY Laura Sussman

An advanced form of image-guided radiation therapy known as intensity modulated proton therapy (IMPT) has shown early promise for the treatment...

BY Scott Merville

Extensive genomic analysis led by MD Anderson researchers has opened new avenues to explore in the treatment of a rare and tenaciously lethal...